DSIP

WAGGDASGE nonapeptide research reference · sleep-related pharmacology remains unresolved

Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COACAS 62568-57-4RUO

Research statusExploratory historical evidence; endogenous receptor and physiological role remain unresolved; laboratory Research Use Only

Supplied formLinear nonapeptide; H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH

Lead time10–18 days

DSIP — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA

DSIP — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include analytical identity and impurity-method development, replication of historical sleep-study observations, investigation of rapid peptide degradation, and carefully controlled study of proposed neuroendocrine or stress-related pathways
Reported sleep, analgesia, endocrine or withdrawal findings remain model- and study-specific and are not product benefits or treatment claims.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 62568-57-4
Formula: C₃₅H₄₈N₁₀O₁₅
Molecular weight: Approximately 848.8 Da
Appearance: Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA
Purity: Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COA
Storage: Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and any prepared-solution hold time require evidence for the exact form, matrix and concentration; no universal 2–8 °C, 14-day or post-reconstitution rule applies.
MOQ: On request
Lead time: 10–18 days

PubChem CID 68816

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about DSIP

DSIP is the sequence-defined nonapeptide H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH, historically isolated and compared with synthetic material in the 1970s. PubChem CID 68816 and FDA's 2026 chemistry review support formula C₃₅H₄₈N₁₀O₁₅, average molecular weight about 848.8 Da and CAS 62568-57-4 for emideltide free base; acetate is a distinct bulk drug substance and must not be inferred from the common name alone. Decades of sleep, stress, endocrine and withdrawal literature remain difficult to reproduce and interpret: no confirmed endogenous precursor, gene or receptor has been established, and human studies are small and heterogeneous. FDA's May 11, 2026 briefing proposes not adding either free base or acetate to the 503A Bulks List because of characterization, effectiveness and safety-data gaps. PCAC discussion remains scheduled for July 24, 2026; the proposal is not yet a final FDA determination.

Sequence and identity qualification; stability-indicating analytical methods; controlled replication of historical sleep-study observations; and exploratory laboratory study of degradation, neuroendocrine, stress or withdrawal hypotheses
These are research applications, not clinical indications.

Mechanism context

The question the literature is testing

No confirmed DSIP receptor, endogenous precursor or gene has been identified. Proposed GABAergic, monoaminergic, adenosine, opioid and hypothalamic-pituitary-adrenal involvement remains hypothesis-level and method dependent. A short measured degradation time does not prove a receptor-triggered long-duration effect, and pathway hypotheses must not be represented as an established causal mechanism.

Evidence map

Research routes and exposure context

Evidence tierAnalytical / laboratory context

Research areaNeurocognitive research

Routes reported in sources

Intravenous

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use
Small early studies do not establish long-term safety, pregnancy safety, interaction risk, dependence potential or safe operating restrictions
FDA's May 11, 2026 briefing found no safety data for the nominated subcutaneous route, identified potential aggregation, peptide-impurity, immunogenicity and endotoxin-control concerns, and proposed not adding either free base or acetate to the 503A Bulks List
The July 24 PCAC discussion and FDA's later final determination remain pending
Follow the released-lot SDS and institutional risk assessment.

Interactions reported in the literature

No controlled DSIP combination or patient drug-interaction programme was identified
Pairings with melatonin, Selank, Epitalon, Semax, growth-hormone-related peptides, GABAergic agents or opioids are not validated compatibility or safety guidance.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

DSIP factory batch COAs

DSIP 12 mg Factory batch COA protected preview

DSIP12 mg · WHJLP-DS12-260429-E

DSIP 2 mg Factory batch COA protected preview

DSIP2 mg · WHJLP-DS2-260427-D

DSIP 5 mg Factory batch COA protected preview

DSIP5 mg · WHJLP-DS5-260427-D

DSIP 10 mg Factory batch COA protected preview

DSIP10 mg · WHJLP-DS10-260427-D

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require exact WAGGDASGE sequence and termini, supplied form/counterion, theoretical and observed high-resolution intact mass, orthogonal sequence evidence where appropriate, stability-indicating HPLC purity and impurity profile, quantitative peptide content, water/counterion/residuals and lot-specific stability
Sterility, bacterial endotoxin and particulate claims require separate released-lot tests
White appearance, a clear prepared solution or a generic ≥99% area result cannot establish identity or suitability.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

DSIP-02MG2 mg10 vials

DSIP-05MG5 mg10 vials

DSIP-10MG10 mg10 vials

DSIP-12MG12 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and any prepared-solution hold time require evidence for the exact form, matrix and concentration; no universal 2–8 °C, 14-day or post-reconstitution rule applies.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CID 68816, FDA's May 11, 2026 emideltide briefing and the 1977–1978 Schoenenberger-Monnier papers. Human sleep context: PubMed PMID 6895513, PMID 7028502 and the small 1992 chronic-insomnia study, PMID 1299794. Critical synthesis: PMID 16539679. Method-dependent degradation: PMID 25463 and PMID 3628078. Regulatory status: FDA's May 11 briefing, the April 16, 2026 Federal Register notice and the FDA PCAC calendar for July 23–24, 2026. Each source must retain its exact material, form, model and limitations.

01
Characterization of a delta-electroencephalogram (-sleep)-inducing peptide
Proceedings of the National Academy of Sciences of the United States of America (PNAS) · 1977 · peer-reviewed original research (landmark discovery paper)
Open source
02
The delta sleep inducing peptide (DSIP): comparative properties of the original and synthetic nonapeptide
Experientia · 1977 · peer-reviewed original research
Open source
03
The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide
Pflügers Archiv - European Journal of Physiology · 1978 · peer-reviewed original research
Open source
04
Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
International Journal of Clinical Pharmacology, Therapy, and Toxicology · 1981 · peer-reviewed original research (double-blind crossover clinical trial, healthy volunteers)
Open source
05
The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep
Experientia · 1981 · peer-reviewed original research (clinical trial, chronic insomniacs)
Open source
06
Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors
Neuropsychobiology · 1983 · peer-reviewed original research (open clinical case series, alcohol/opiate withdrawal)
Open source
07
Delta-sleep-inducing peptide (DSIP): a review
Neuroscience & Biobehavioral Reviews · 1984 · peer-reviewed systematic/narrative review
Open source
08
Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Journal of Neurochemistry · 2006 · peer-reviewed critical review
Open source

Product FAQ

Questions buyers ask about DSIP

What chemical identity should be confirmed for DSIP?+

PubChem CID 68816 supports the free nonapeptide WAGGDASGE, sequence H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH, formula C₃₅H₄₈N₁₀O₁₅, average molecular weight about 848.8 Da and CAS 62568-57-4. The order must still state exact termini, supplied salt or counterion, water basis and net peptide-content basis; the released-lot COA should reconcile theoretical and observed mass.

DSIP

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about DSIP

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

DSIP factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Characterization of a delta-electroencephalogram (-sleep)-inducing peptide

The delta sleep inducing peptide (DSIP): comparative properties of the original and synthetic nonapeptide

The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide

Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior

The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep

Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors

Delta-sleep-inducing peptide (DSIP): a review

Delta sleep-inducing peptide (DSIP): a still unresolved riddle

Questions buyers ask about DSIP

Compare adjacent molecules and documentation needs.

Semax

Selank

P21 (P021)

PE-22-28